PEER-REVIEW REPORT

Name of journal: World Journal of Virology
Manuscript NO: 68838
Title: Management of SARS-CoV-2 infection is a major challenge in patients with lymphoid malignancies: Warrants a clear therapeutic strategy
Provenance and peer review: Invited manuscript; Externally peer reviewed
Peer-review model: Single blind
Reviewer’s code: 06060139
Position: Peer Reviewer
Academic degree: MD
Professional title: Doctor
Reviewer’s Country/Territory: India
Author’s Country/Territory: Germany
Manuscript submission date: 2021-06-05
Reviewer chosen by: AI Technique
Reviewer accepted review: 2021-06-06 12:03
Reviewer performed review: 2021-06-06 12:04
Review time: 1 Hour

<table>
<thead>
<tr>
<th>Scientific quality</th>
<th>[ ] Grade A: Excellent</th>
<th>[ ] Grade B: Very good</th>
<th>[ ] Grade C: Good</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>[ ] Grade D: Fair</td>
<td>[ ] Grade E: Do not publish</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Language quality</th>
<th>[ ] Grade A: Priority publishing</th>
<th>[ ] Grade B: Minor language polishing</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>[ ] Grade C: A great deal of language polishing</td>
<td>[ ] Grade D: Rejection</td>
</tr>
</tbody>
</table>

Conclusion
[ ] Accept (High priority) [ ] Accept (General priority)
[ ] Minor revision [ ] Major revision [ ] Rejection

Re-review
[ ] Yes [ ] No
SPECIFIC COMMENTS TO AUTHORS
The manuscript is well written and need of the present times.
## Name of journal: World Journal of Virology

**Manuscript NO:** 68838

**Title:** Management of SARS-CoV-2 infection is a major challenge in patients with lymphoid malignancies: Warrants a clear therapeutic strategy

**Provenance and peer review:** Invited manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer’s code:** 05935566

**Position:** Peer Reviewer

**Academic degree:** MBBS, MS

**Professional title:** Assistant Professor, Doctor

**Reviewer’s Country/Territory:** India

**Author’s Country/Territory:** Germany

**Manuscript submission date:** 2021-06-05

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2021-06-07 04:41

**Reviewer performed review:** 2021-06-07 07:54

**Review time:** 3 Hours

<table>
<thead>
<tr>
<th>Scientific quality</th>
<th>[ ] Grade A: Excellent</th>
<th>[ ] Grade B: Very good</th>
<th>[ ] Grade C: Good</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>[ ] Grade D: Fair</td>
<td>[ ] Grade E: Do not publish</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Language quality</th>
<th>[ ] Grade A: Priority publishing</th>
<th>[ ] Grade B: Minor language polishing</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>[ ] Grade C: A great deal of language polishing</td>
<td>[ ] Grade D: Rejection</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Conclusion</th>
<th>[ ] Accept (High priority)</th>
<th>[ ] Accept (General priority)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>[ ] Minor revision</td>
<td>[ ] Major revision</td>
</tr>
</tbody>
</table>

| Re-review                   | [ ] Yes | [ ] No |


SPECIFIC COMMENTS TO AUTHORS
Dear author, Well written article Regards
PEER-REVIEW REPORT

Name of journal: World Journal of Virology

Manuscript NO: 68838

Title: Management of SARS-CoV-2 infection is a major challenge in patients with lymphoid malignancies: Warrants a clear therapeutic strategy

Provenance and peer review: Invited manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer’s code: 05401746

Position: Peer Reviewer

Academic degree: BM BCh, MA, MRCP, PhD

Professional title: Associate Professor, Consultant Physician-Scientist, Senior Lecturer

Reviewer’s Country/Territory: United Kingdom

Author’s Country/Territory: Germany

Manuscript submission date: 2021-06-05

Reviewer chosen by: AI Technique

Reviewer accepted review: 2021-06-07 15:40

Reviewer performed review: 2021-06-15 17:28

Review time: 8 Days and 1 Hour

Scientific quality

- Grade A: Excellent
- Grade B: Very good
- Grade C: Good
- Grade D: Fair
- Grade E: Do not publish

Language quality

- Grade A: Priority publishing
- Grade B: Minor language polishing
- Grade C: A great deal of language polishing
- Grade D: Rejection

Conclusion

- Accept (High priority)
- Accept (General priority)
- Minor revision
- Major revision
- Rejection

Re-review

- Yes
- No
SPECIFIC COMMENTS TO AUTHORS

Sahu and colleagues have authored a letter in response to a recent review in this journal. The letter makes a few good points but there are a few errors which need attention - Given the title it would be useful if the authors could make some suggestions as to what this therapeutic strategy might involve - The article by Abid et al that they reference several times is a viewpoint and does not contain original data. In addition it reviews COVID-19 treatment in the context of immune checkpoint blockade and CAR T cells and makes a few recommendations for this type of treatment - it does not mention standard chemo(immuno)therapy which the vast majority of lymphoma patients will receive - They reference this paper again after quoting figures that 85% of patients with lymphoid malignancies will be admitted with 9% needing ICU and 34.5% mortality - but these figures are not in this reference - They touch on the efficacy of COVID-19 vaccines in lymphoma patients as a result of very recent publications. As this data has been published since the Riches review this would be a good area to expand upon